07:00 , Aug 10, 2015 |  BioCentury  |  Finance

And then there were two

After 20 years and about $1.3 billion raised, Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) has had its first Phase III success with telotristat etiprate to treat carcinoid syndrome. The company hopes to double its Phase III hit...
02:34 , Oct 18, 2014 |  BC Extra  |  Company News

VC tracks

Canaan Partners promoted Tim Shannon to general partner and Julie Papanek to principal on the healthcare team. Shannon joined Canaan in 2009 after serving as CEO of CuraGen Corp. through its sale to Celldex Therapeutics...
08:00 , Dec 20, 2010 |  BioCentury  |  Strategy

TAP's Big Finish

It has taken nearly three decades, but ImmunoGen Inc. is finally getting some traction with its TAP targeted antibody payload platform. The company has closed out 2010 with a rush of news, and now intends...
08:00 , Feb 22, 2010 |  BC Week In Review  |  Company News

Celldex, TopoTarget deal

Celldex received a $3 million sublicense payment from TopoTarget after TopoTarget's deal earlier this month with Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI, Irvine, Calif.) to co-develop and commercialize belinostat in North America and India. In 2008, TopoTarget...
08:00 , Feb 8, 2010 |  BC Week In Review  |  Company News

Spectrum Pharmaceuticals, Topotarget deal

Spectrum received rights to co-develop and commercialize TopoTarget's belinostat in North America and India, with an option for China. The histone deacetylase (HDAC) inhibitor is in Phase III testing for peripheral T cell lymphoma (PTCL),...
08:00 , Dec 21, 2009 |  BC Week In Review  |  Clinical News

CDX-011: Phase II data

In 26 evaluable patients from the Phase II portion of a Phase I/II trial, 1.88 mg/kg IV CDX-011 met the primary endpoint, which required >=5 of 25 (20%) patients in the Phase II portion to...
08:00 , Dec 7, 2009 |  BioCentury  |  Finance

Ebb & Flow

The latest follow-on from Human Genome Sciences Inc. (NASDAQ:HGSI) will increase its cash to around $1.1 billion, more than enough to get Benlysta belimumab to market for systemic lupus erythematosus. Indeed, if all goes well,...
07:00 , Oct 5, 2009 |  BC Week In Review  |  Company News

Celldex, CuraGen deal

Celldex completed its previously announced acquisition of fellow cancer company CuraGen for about $93.5 million in a stock (see BioCentury, June 1). Celldex Therapeutics Inc. (NASDAQ:CLDX), Needham, Mass.   CuraGen Corp. (NASDAQ:CRGN), Branford, Conn.  ...
07:00 , Jun 8, 2009 |  BC Week In Review  |  Clinical News

CR011-vcMMAE: Additional Phase I/II data

Additional data from 36 patients in the open-label Phase II portion of an ongoing U.S. Phase I/II trial showed that IV CR011-vcMMAE produced 3 partial responses (PR), 1 unconfirmed PR and 19 cases of stable...
07:00 , Jun 1, 2009 |  BC Week In Review  |  Company News

Celldex, CuraGen deal

Celldex will acquire fellow cancer company CuraGen in a stock deal that Celldex said values CuraGen at $94.5 million. Based on CuraGen's 57.2 million shares outstanding at May 8, the deal values CuraGen at $1.65...